Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Can J Physiol Pharmacol ; 97(11): 1073-1079, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31536393

ABSTRACT

This study aimed to investigate the effects of propofol through evaluating its interaction with nitric oxide (NO), hydrogen sulfide (H2S), and carbon monoxide (CO). Wistar male rats were divided in 4 groups: (1) bolus injection of propofol (1% 10 mg/mL, 100 mg/kg bw, i.p.); (2) Nω-nitro-l-arginine methyl ester (L-NAME; NO synthase inhibitor, 60 mg/kg bw, i.p.) + bolus injection of propofol (1% 10 mg/mL, 100 mg/kg bw, i.p.); (3) DL-propargylglycine (DL-PAG; H2S synthase inhibitor, 50 mg/kg bw, i.p.) + bolus injection of propofol (1% 10 mg/mL, 100 mg/kg bw, i.p.); (4) zinc protoporphyrin IX (ZnPPIX; CO synthase inhibitor, 50 µmol/kg bw, i.p.) + bolus injection of propofol (1% 10 mg/mL, 100 mg/kg bw, i.p.). Increased levels of albumins, low-density lipoproteins, alkaline phosphatase, amylase, high-sensitivity Troponin T, and fibrinogen were found in L-NAME + propofol group. Platelet crit, platelet count, total cholesterol, and high-density lipoproteins were elevated in ZnPPIX + propofol group. Hydrogen peroxide was increased in all groups treated with gasotransmitters inhibitors. Reduced glutathione was reduced in all groups, superoxide dismutase activity only in L-NAME + propofol. The effect of propofol on various biochemical, haematological, and oxidative stress markers may be at least in part mediated through interaction with 3 estimated gasotransmitters.


Subject(s)
Anesthetics/pharmacology , Gasotransmitters/antagonists & inhibitors , Hematologic Tests , Oxidative Stress/drug effects , Propofol/pharmacology , Animals , Biomarkers/blood , Hemostasis/drug effects , Homocysteine/blood , Male , Rats , Rats, Wistar
2.
Dig Dis Sci ; 62(9): 2223-2230, 2017 09.
Article in English | MEDLINE | ID: mdl-28733867

ABSTRACT

Of the numerous gaseous substances that can act as signaling molecules, the best characterized are nitric oxide, carbon monoxide and hydrogen sulfide. Contributions of each of these low molecular weight substances, alone or in combination, to maintenance of gastrointestinal mucosal integrity have been established. There is considerable overlap in the actions of these gases in modulating mucosal defense and responses to injury, and in some instances they act in a cooperative manner. Each also play important roles in regulating inflammatory and repair processes throughout the gastrointestinal tract. In recent years, significant progress has been made in the development of novel anti-inflammatory and cytoprotective drugs that exploit the beneficial activities of one or more of these gaseous mediators.


Subject(s)
Carbon Monoxide/metabolism , Gasotransmitters/metabolism , Gastrointestinal Tract/metabolism , Hydrogen Sulfide/metabolism , Nitric Oxide/metabolism , Animals , Carbon Monoxide/antagonists & inhibitors , Gasotransmitters/antagonists & inhibitors , Gastric Mucosa/drug effects , Gastric Mucosa/metabolism , Gastric Mucosa/pathology , Gastrointestinal Agents/pharmacology , Gastrointestinal Agents/therapeutic use , Gastrointestinal Tract/drug effects , Gastrointestinal Tract/pathology , Humans , Hydrogen Sulfide/antagonists & inhibitors , Inflammation/drug therapy , Inflammation/metabolism , Inflammation/pathology , Intestinal Mucosa/drug effects , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Nitric Oxide/antagonists & inhibitors
3.
Nat Rev Drug Discov ; 15(3): 185-203, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26678620

ABSTRACT

The three endogenous gaseous transmitters - nitric oxide (NO), carbon monoxide (CO) and hydrogen sulfide (H2S) - regulate a number of key biological functions. Emerging data have revealed several new mechanisms for each of these three gasotransmitters in tumour biology. It is now appreciated that they show bimodal pharmacological character in cancer, in that not only the inhibition of their biosynthesis but also elevation of their concentration beyond a certain threshold can exert anticancer effects. This Review discusses the role of each gasotransmitter in cancer and the effects of pharmacological agents - some of which are in early-stage clinical studies - that modulate the levels of each gasotransmitter. A clearer understanding of the pharmacological character of these three gases and the mechanisms underlying their biological effects is expected to guide further clinical translation.


Subject(s)
Gasotransmitters/biosynthesis , Neoplasms/metabolism , Neoplasms/physiopathology , Therapies, Investigational/methods , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Agents/therapeutic use , Carbon Monoxide/antagonists & inhibitors , Carbon Monoxide/metabolism , Gasotransmitters/antagonists & inhibitors , Humans , Hydrogen Sulfide/antagonists & inhibitors , Hydrogen Sulfide/metabolism , Neoplasms/therapy , Nitric Oxide/antagonists & inhibitors , Nitric Oxide/metabolism , Therapies, Investigational/trends
SELECTION OF CITATIONS
SEARCH DETAIL
...